Gilead Sciences | GILD - Current Assets

Stock Price
148.20
Daily Change
-1.67 -1.11%
Monthly
7.56%
Yearly
33.48%
Q1 Forecast
146.71

Gilead Sciences reported $19.89B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 460.96M 80.75M Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025